PD-L1 and TMB are independent biomarkers of response to immunotherapy in most cancer types, and the combination of both may be better at predicting outcomes than any single biomarker. In our study, there was no correlation between TMB and PD-L1 levels, similar to previous results in unselected populations for TMB. Here, CD274 is linked to cancer.